Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 238Biopsy 197Nivolumab 58Cyclophosphamide 53X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 32Gemcitabine 32atezolizumab 31CTLA-4 Antigen 31olaparib 28fludarabine 28venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Procarbazine × 90 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡